Cogent Biosciences, Inc. Common Stock
COGTCogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for rare genetic diseases and cancers. The company's research centers on precision medicines that inhibit specific kinases involved in disease pathways, with a particular emphasis on conditions such as systemic mastocytosis and other tumor-related disorders. Founded to leverage insights into kinase biology, Cogent aims to deliver personalized treatment options for patients with limited or no effective therapies.
Company News
Cogent Biosciences announced preclinical data presentations at the 2026 AACR Annual Meeting for two pipeline programs: CGT1263, a pan-KRAS(ON) inhibitor showing >500x selectivity over HRAS/NRAS with potential to reduce skin toxicity, and CGT4255, a brain-penetrant ErbB2 inhibitor demonstrating synergistic activity with HER2 ADCs. The company expe...
RTW Investments made a significant $116 million purchase of Cogent Biosciences shares in Q4, increasing its stake to 2.7% of AUM. The move signals confidence in the biotech company's lead drug candidate (CGT9486) and upcoming FDA decision timeline in late 2026. Cogent's stock has surged 360% over the past year, and the company has $900 million in...
Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinic...
Cogent Biosciences stock surged 5.24% after the FDA accepted its New Drug Application for bezuclastinib, a treatment for Non-Advanced Systemic Mastocytosis. The FDA decision is expected by December 30, 2026, with no advisory committee meeting planned. The company also plans to submit additional NDAs for GIST and Advanced Systemic Mastocytosis tre...
Cogent Biosciences announced additional clinical results from the SUMMIT trial showing bezuclastinib achieved a mean TSS reduction of -32.0 points at 48 weeks, with 99% of patients achieving >50% reduction in serum tryptase and 83% achieving normalization. The data demonstrates consistent symptomatic improvements across multiple organ systems and...
Related Companies
